Pharmacokinetic studies of coagulation factors: Relevance of plasma and extracellular volume and body weight

Haemophilia

Volumn 12, Issue SUPPL. 4, 2006, Pages 33-39

  Komwilaisak, P ^a   Blanchette, Victor ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Blood volume; Children; Haemophilia; Obesity; Pharmacokinetic (PK); Plasma volume

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ARTICLE; BLOOD VOLUME; BODY HEIGHT; BODY WEIGHT; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; ERYTHROCYTE VOLUME; EXTRACELLULAR SPACE; HEMATOCRIT; HEMOPHILIA A; HUMAN; LEAN BODY WEIGHT; LIVER WEIGHT; OBESITY; PLASMA VOLUME; PRIORITY JOURNAL;

EID: 33748764395     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01332.x     Document Type: Article

References (32)

1. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. New Engl J Med 2003; 349: 1157-67.
2. International Committee for Standardization in Haematology. Recommended methods for measurement of red-cell and plasma volume. J Nucl Med 1980; 21: 793-800.
3. Mollison PL, Engelfriet CP, Contreras M (eds). Blood Volume. Blood Transfusion in Clinical Medicine, 8th edn. Oxford: Blackwell Scientific Publications, 1988: 68-94.
4. Mollison PL, Veall N, Cutbush M. Red cell and plasma volume in newborn infants. Arch Dis Child 1950; 25: 242-53.
5. Bratteby L-E. Studies on erythro-kinetics in infancy. Acta Paediatr Scand 1968; 57: 132-6.
6. Usher R, Shephard M, Lind J. The blood volume of the newborn infant and placental transfusion. Acta Paediatr 1963; 52: 497-512.
7. Huber H, Lewis SM, Szur L. The influence of anaemia, polycythaemia and splenomegaly on the relationship between venous haematocrit and red-cell volume. Br J Haematol 1964; 10: 567-75.
8. Blanchette VS, Zipursky A. Assessment of anemia in newborn infants. Clin Perinatol 1984; 11: 489-510.
9. Kjellman H. Calculations of factor VIII in vivo recovery and half-life. Scand J Haematol 1984; 33 (Suppl. 40): 165-74.
10. Messori A, Longo G, Matucci M, Morfini M, Ferrini PLR. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
11. Prowse CV on behalf of the Subcommittee on factor VIII and IX of the Scientific and Standardization Committee of the ISTH. In vivo recovery of factor VIII following transfusion: A survey of recent data and publications to assess the influence of standards used for potency assignment. Thromb Haemost 1995; 74: 1191-6.
12. Lee ML. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost 1993; 69: 87.
13. Lee M, Morfini M, Schulman S, Ingerslev J. and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis Scientific and Standardization Committee communication. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Posted on ISTH Website 21 March, 2001. Available at http://www.med.unc.edu/isth/SSC/communications/factor8and9/ fviiipharmaco.pdf.
14. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 1984; 247: F632-6.
15. Hume R, Goldberg A. Actual and predicted normal red-cell and plasma volumes in primary and secondary polycythemia. Clin Sci 1964; 26: 499-508.
16. Morfini M, Lee M, Messori A and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6.
17. Schindel F. Consideration of endogenous backgrounds in pharmacokinetic analyses: A simulation study. Eur J Clin Pharmacol 2000; 56: 685-8.
18. Pencharz P. Drug dosing in children-special considerations. Haemophilia 2006; 12 (Suppl. 4): 30-2.
19. Takahashi H, Ishikawa S, Nomoto S et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000; 68: 541-55.
20. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995; 23: 1110-6.
21. Liesner R, Shapiro A, Blanchette V et al. Efficacy, safety and pharmacokinetic properties of ADVATE rAHF-PFM in previously treated patients (PTPs) less than 6 years of age. Journal Thromb Haemost 2005; 3 (Suppl. 1): 183.
22. A Position Paper by the Ontario Medical Association. An ounce of prevention or a ton of trouble: Is there an epidemic of obesity in children? Ont Med Rev 2005; 72: 32-44.
23. Komwilaisak P, Steele M, Cottingham D, Wakefield C, Blanchette V, Ling SC. The prevalence of liver disease in children with hemophilia. Haemophilia 2006; 12 (Suppl. 2): 32 PO 970. Available online at (http://www.blackwell-synergy.com/doi/pdf/10.111/ j1335-0691.2006.01251_1.x)
24. Moore DJ, Durie PR, Forstner GG, Pencharz PB. The assessment of nutritional status in children. Nutr Res 1985; 5: 797-9.
25. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37.
26. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
27. Vlot AJ, Mauser-Bunchoten EP, Zarkova AG et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group 0 than in those with blood group A. Thromb Haemost 2000; 83: 65-9.
28. Tuddenham EGD, Lane RS, Rotblat F et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophila A and von Willebrand's disease. Br J Haematol 1982; 52: 259-67.
29. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparin sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 11970-9.
30. Poon M-C, Lillicrap D, Hensman C, Card R, Scully M-F. Members of Association of Hemophilia Clinic Directors of Canada and Canadian Association of Nurses in Hemophilia Care. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
31. Manno CS, Butler RB, Cohen AR. Low recovery in vivo of highly purified factor VIII in patients with hemophilia. J Pediatr 1992; 121: 814-8.
32. Dallman PR. Blood and blood-forming tissues. In: Rudolph A, ed. Pediatrics, 16th edn. New York: Appleton-Century-Crofts, 1977: 1111.